A
Anne Cayre
Researcher at French Institute of Health and Medical Research
Publications - 88
Citations - 4272
Anne Cayre is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 27, co-authored 84 publications receiving 3957 citations. Previous affiliations of Anne Cayre include University of Auvergne.
Papers
More filters
Journal ArticleDOI
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Astrid Lièvre,Jean-Baptiste Bachet,Valérie Boige,Anne Cayre,Delphine Le Corre,Emmanuel Buc,Marc Ychou,Olivier Bouché,Bruno Landi,Christophe Louvet,Thierry André,Frédéric Bibeau,Marie-Danièle Diebold,Philippe Rougier,Michel Ducreux,Gorana Tomasic,Jean-François Emile,Frédérique Penault-Llorca,Pierre Laurent-Puig +18 more
TL;DR: These results confirm the high prognostic value of KRAS mutations on response to cetuximab and survival in metastatic CRC patients treated with cetUXimab.
Journal ArticleDOI
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig,Anne Cayre,Gilles Manceau,Emmanuel Buc,Jean-Baptiste Bachet,Thierry Lecomte,Philippe Rougier,Astrid Lièvre,Bruno Landi,Valérie Boige,Michel Ducreux,Marc Ychou,Frédéric Bibeau,Olivier Bouché,Julia Reid,Steven Stone,Frédérique Penault-Llorca +16 more
TL;DR: Braf status, EGFR amplification, and cytoplasmic expression of PTEN were associated with outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen, and subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.
Journal ArticleDOI
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Michèle Beau-Faller,Nathalie Prim,A.-M. Ruppert,Isabelle Nanni-Metellus,Roger Lacave,Ludovic Lacroix,Fabienne Escande,Sarab Lizard,Jean-Luc Prétet,Isabelle Rouquette,P. de Cremoux,Jérôme Solassol,F. De Fraipont,Ivan Bièche,Anne Cayre,E. Favre-Guillevin,Pascale Tomasini,Marie Wislez,Benjamin Besse,Michèle Legrain,Anne-Claire Voegeli,Laurence Baudrin,Franck Morin,Gérard Zalcman,Elisabeth Quoix,Hélène Blons,Jacques Cadranel +26 more
TL;DR: Rare EGfr-mutated NSCLCs are heterogeneous, with resistance of distal exon 20 insertions and better sensitivity of exon 18 or complex mutations to EGFR-TKIs, probably requiring individual assessment.
Journal ArticleDOI
Does inhibition of P-glycoprotein lead to drug-drug interactions?
TL;DR: Concomitant administration of substrates and Pgp inhibitors would modify drug pharmacokinetics by increasing bioavailability and organ uptake, leading to more adverse drug reactions and toxicities.
Journal ArticleDOI
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane based chemotherapy in operable triple negative breast cancer: Identification of biologically-defined signatures predicting treatment impact
J-M Nabholtz,Catherine Abrial,Marie-Ange Mouret-Reynier,M.M. Dauplat,Bettina Weber,Joseph Gligorov,A. M. Forest,Olivier Tredan,Laurence Vanlemmens,Thierry Petit,Séverine Guiu,I. van Praagh,Christelle Jouannaud,Pascale Dubray-Longeras,Nicole Tubiana-Mathieu,K.E. Benmammar,Sharif Kullab,M.R.K. Bahadoor,Nina Radosevic-Robin,Fabrice Kwiatkowski,A. Desrichard,Anne Cayre,Nancy Uhrhammer,N. Chalabi,Philippe Chollet,Philippe Chollet,Frédérique Penault-Llorca +26 more
TL;DR: Panitumumab in combination with FEC100 followed by docetaxel appears efficacious, with acceptable toxicity, as neoadjuvant therapy of operable TNBC, suggesting a potential interest to further develop this combination in biologically defined subgroups of patients with TNBC.